

Datasheet for ABIN7194934

**CD70 Protein (Fc Tag)**[Go to Product page](#)**1** Image

## Overview

Quantity:	50 µg
Target:	CD70
Origin:	Mouse
Source:	HEK-293 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Purification tag / Conjugate:	This CD70 protein is labelled with Fc Tag.

## Product Details

Purpose:	Recombinant Mouse TNFSF7/CD70 Protein (Fc Tag)(Active)
Sequence:	Gln47-Pro195
Characteristics:	A DNA sequence encoding the mouse Cd70 (NP_035747.1) (Gln47-Pro195) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Purity:	> (12.5+86.3) % as determined by SDS-PAGE
Endotoxin Level:	< 1.0 EU per µg of the protein as determined by the LAL method.
Biological Activity Comment:	1.Measured by its binding ability in a functional ELISA.2.Immobilized mouse CD27-His at 10µg/mL (100µL/well) can bind mouse CD70 , the EC50 of mouse CD70 is 10-50 ng/mL.

## Target Details

Target:	CD70
---------	------

## Target Details


Alternative Name:	TNFSF7/CD70 ( <a href="#">CD70 Products</a> )
Background:	<p>Background: CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.</p> <p><a href="#">Immune Checkpoint</a><a href="#">Immune Checkpoint</a> <a href="#">Proteins</a><a href="#">Immune Checkpoint Targets</a> <a href="#">Co-stimulatory Immune Checkpoint Targets</a> <a href="#">Immunotherapy</a> <a href="#">Cancer Immunotherapy</a> <a href="#">Targeted Therapy</a></p> <p>Synonym: Cd27l;CD27LG;Tnfsf7</p>
Molecular Weight:	43.1 kDa
NCBI Accession:	<a href="#">NP_035747</a>
Pathways:	<a href="#">Cancer Immune Checkpoints</a>

## Application Details

Restrictions:	For Research Use only
---------------	-----------------------

## Handling

Format:	Lyophilized
Reconstitution:	Please refer to the printed manual for detailed information.
Buffer:	Lyophilized from sterile PBS, pH 7.4
Storage:	4 °C,-20 °C,-80 °C
Storage Comment:	<p>Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at &lt; -20°C for 3 months.</p>



Western Blotting

Image 1.